← Back to patent-cliff list
Quabodepistat
Tier C — Watch / tradeQuabodepistat
Otsuka Holdings Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DprE1
Indications (approved)：Multidrug-resistant tuberculosis, Pulmonary tuberculosis, Mycobacterium tuberculosis infection
Regional status
US
Phase I
2022-09-19
EU
Phase III
2026-01-16
China
Phase III
2025-10-16
Japan
Phase III
2025-10-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Quabodepistat?
Approved indications include: Multidrug-resistant tuberculosis, Pulmonary tuberculosis, Mycobacterium tuberculosis infection.
When does the Quabodepistat patent expire?
No public expiry year is available for Quabodepistat yet; this page updates once verified.
How do I get a quote for Quabodepistat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30